<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497288</url>
  </required_header>
  <id_info>
    <org_study_id>FT-1301-101-RD</org_study_id>
    <secondary_id>2011-002549-37</secondary_id>
    <secondary_id>U1111-1135-2623</secondary_id>
    <nct_id>NCT01497288</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects</brief_title>
  <acronym>PK400 INFS</acronym>
  <official_title>An Open Label, Randomised, Single-centre, Two Sequence, Cross-over Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects Using a Population PK Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The overall clinical trial objective is to gain information about the Pharmacokinetics (PK)
      of a 400 µg dose strength of INFS using a Population PK (PopPK). In total, 20 healthy male
      and female subjects are planned to be randomized in the trial. Subjects will be randomized to
      one of two treatment sequences and treated with 3 different dosages (either 200 µg/dose INFS,
      400 µg/dose or 400 µg two doses administered 10 minutes apart) over two days. Subjects will
      be hospitalized over a period of total 5 days, where safety assessments and pharmacokinetic
      samplings will be conducted.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - inf)]</measure>
    <time_frame>Blood sampling for PK will be performed until 72 hours after the first treatment administration</time_frame>
    <description>AUC= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from simulated single dose concentration time profiles derived from the final parameters of the PopPK model [clearance (CL), absorption rate constant (KA), central volume (V2), and bioavailability (F1)].</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence 1 (A-B-C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1
B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment
C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 (A-C-B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1
C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment
B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INFS (Intranasal Fentanyl Spray)</intervention_name>
    <description>Intranasal Fentanyl Spray</description>
    <arm_group_label>Sequence 1 (A-B-C)</arm_group_label>
    <arm_group_label>Sequence 2 (A-C-B)</arm_group_label>
    <other_name>(Instanyl®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

        Healthy male and female Caucasian or Black subjects between 18 and 55 years with a body
        mass index of 18-28 kg/m2 and a minimum weight of 50 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intranasal fentanyl spray</keyword>
  <keyword>Population PK</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

